Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00592332 · ClinicalTrials.gov registry record · NA
Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT00592332 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 56 participants.
The verdict
NCT00592332, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
Alprazolam (Xanax) will blunt the body's ability to defend itself from low blood sugar.
Interventions
- DRUG Alprazolam
- OTHER control group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00592332
The ClinicalTrials.gov registry entry for NCT00592332 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alprazolam is the first listed.
NCT00592332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00592332 about?
NCT00592332 is a clinical study titled "Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2". Alprazolam (Xanax) will blunt the body's ability to defend itself from low blood sugar.
What is the current status of trial NCT00592332?
This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2005-06. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00592332?
The interventions under investigation include: Alprazolam (DRUG), control group (OTHER).
Who is sponsoring clinical trial NCT00592332?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.